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The interleukin 7 receptor alpha chain (IL-7Rα) is predominately expressed by lymphocytes, and 
activation by its ligand IL-7 supports the development and maintenance of T cells and boosts T-cell 
mediated immunity. We recently reported that lymphatic endothelial cells (LECs) in dermal lymphatics 
also express IL-7 and its receptor chains (IL-7Rα and CD132) and that IL-7 supports lymphatic drainage. 
This suggested that activation of IL-7Rα signaling in lymphatics could exert inflammation-resolving 
activity, by promoting the clearance of excess tissue fluid. Here we investigated how the potentially 
opposing effects of IL-7Rα signaling in immune cells and in the lymphatic vasculature would affect 
the development and progression of psoriasis-like skin inflammation. We found that during acute 
and chronic skin inflammation mice with an endothelial-specific deletion of IL-7Rα (IL-7RαΔec 
mice) developed more edema compared to control mice, as a consequence of impaired lymphatic 
drainage. However, systemic treatment of wild-type mice with IL-7 exacerbated edema and immune 
cell infiltration in spite of increasing lymphatic drainage, whereas treatment with IL-7Rα blocking 
antibody ameliorated inflammatory symptoms. These data identify IL-7Rα signaling as a new 
pathway in psoriasis-like skin inflammation and show that its pro-inflammatory effects on the immune 
compartment override its anti-inflammatory, drainage-enhancing effects on the endothelium.
Afferent lymphatic vessels are present in virtually all tissues of the body and play important roles in the regula-
tion of tissue fluid homeostasis, inflammation and immunity. During an inflammatory response, blood vessels 
become permeable leading to the extravasation of blood-derived fluids, macromolecules and leukocytes into the 
tissue. Lymphatic vessels serve to take up excess fluid as well as immune mediators and leukocytes to facilitate 
their removal from the inflamed tissue and transport to draining lymph nodes (LNs) or beyond. In doing so, lym-
phatic vessels exert important anti-inflammatory functions, as also apparent in lymphedema, where lymphatic 
dysfunction induces chronic inflammatory changes in the affected skin1. Animal studies have recently suggested 
that stimulation of lymphangiogenesis and lymphatic drainage, to remove excess fluids (i.e. edema) and inflam-
matory mediators from the tissue, may offer a novel approach for the treatment of chronic inflammatory diseases: 
Specifically, activation of vascular endothelial growth factor (VEGF) receptor 3 (VEGFR-3) by VEGF-C was 
shown to accelerate the resolution of rheumatoid arthritis2 and inflammatory bowel disease3 and to ameliorate 
acute and chronic skin inflammation4–6 in various mouse models7.
We have recently reported that similarly to VEGF-C, interleukin-7 (IL-7) supports lymphatic drainage func-
tion in vivo8. IL-7 is a pleiotropic cytokine, which is primarily produced by stromal cells in primary and secondary 
lymphoid organs, keratinocytes and epithelial cells9. It is important for T and B cell development, lymph node 
(LN) organogenesis and the survival of naive and memory T cells9,10. Moreover, IL-7 was found to promote 
effector functions of T helper (Th)1 and Th17 cells and of cytotoxic T cells11–14. We recently reported that der-
mal lymphatic endothelial cells (LECs) express both IL-7 as well as its two receptor chains, i.e. the IL-7 receptor 
alpha chain (IL-7Rα) and the common cytokine receptor gamma chain (CD132). Treatment with IL-7 supported 
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lymphangiogenic processes in vitro, and mice with a global deletion of IL-7Rα (IL-7Rα−/−) or overexpression 
of IL-7 in all cell types (IL-7tg mice) displayed alterations in their lymphatic network in the skin and the dia-
phragm (i.e. the two organs analysed)8. We observed that drainage through dermal lymphatic vessels was reduced 
in IL-7Rα−/− mice, while it was enhanced in IL-7tg mice, or upon treatment with recombinant IL-7/anti-IL-7 
complexes8. Our study further revealed that the drainage-enhancing activity of IL-7 was dependent on IL-7Rα 
expression in stromal cells, indicating a direct autocrine action of IL-7 on LECs8.
Enhancing lymphatic drainage by activation of the IL-7Rα signaling pathway could therefore – in analogy 
to VEGF-C4 – represent a novel approach for reducing tissue inflammation. However, in contrast to VEGF-C, 
IL-7 has also been linked to the pathogenesis of a number of autoimmune diseases. Levels of IL-7 or of a soluble 
form of the IL-7Rα reportedly are upregulated in various autoimmune diseases (either in serum or at the site of 
inflammation)13,15 and polymorphisms in the IL-7Rα gene have been associated with the development of multiple 
sclerosis or type I diabetes13,15–17. Conversely, treatment with an IL-7-blocking antibody was shown to confer a 
therapeutic benefit in a mouse model of collagen-induced arthritis (CIA)18, while treatment with IL-7Rα blocking 
antibodies reduced inflammation in mouse models of type 1 diabetes19,20, CIA21, or multiple sclerosis22. Based 
on these findings, an IL-7Rα blocking antibody has recently entered clinical development for the treatment of 
autoimmune conditions23.
Psoriasis is an autoimmune disorder for which the contribution of the IL-7/IL-7Rα signalling pathway has 
not been investigated to date. This disease is triggered by skin-infiltrating autoreactive Th17 cells, which produce 
high levels of inflammatory mediators24, leading to (lymph)angiogenesis, aberrant keratinocyte differentiation/
proliferation and the formation of characteristic erythematous plaques. In the skin, IL-7 is constitutively pro-
duced by epidermal keratinocytes25 as well as by dermal lymphatics8. Interestingly, several studies have previ-
ously reported that IL-7 levels were increased in psoriatic skin and/or in the plasma of psoriasis patients26–28. 
Since edema formation is one of the cardinal signs of inflammation and our previous findings had demonstrated 
that the IL-7/IL-7Rα axis supports lymphatic drainage, we here set out to further investigate the overall role 
of IL-7Rα signaling in psoriasis-like skin inflammation. Specifically, we investigated in three different mouse 
models how the potentially opposing effects of IL-7Rα signaling on immune cells (i.e. immune-stimulating) 
and on the lymphatic vasculature (i.e. drainage-enhancing and inflammation-resolving) would affect the devel-
opment, and progression of psoriasis-like skin inflammation. Our results identify the IL-7Rα signaling axis as 
a new disease-promoting pathway in psoriasis and show that in the context of chronic skin inflammation the 
pro-inflammatory effects of IL-7Rα signaling in the immune compartment override its inflammation-resolving 
and lymphatic drainage-enhancing effects on the endothelium.
Results
Endothelial-specific deletion of IL-7Rα enhances edema formation and decreases lymphatic 
drainage in TPA-induced acute skin inflammation. In our previous work, we had quantified lymphatic 
drainage function by measuring the levels of Evans blue that were retained in the murine ear skin at a defined 
time point after intradermal (i.d.) injection8. In this study, we assessed lymphatic drainage from the ear skin 
with a more dynamic method, namely by measuring the disappearance of an i.d. injected PEGylated infrared 
dye (P20D800) over 24 hours29. In line with our previous findings8, we observed decreased lymphatic drainage 
and an increased half-life in IL-7Rα−/− compared to wild type (WT) mice (Suppl. Fig. 1). Our previous study 
had indicated that the effect of IL-7Rα signaling on lymphatic drainage was dependent on IL-7Rα expression in 
stromal cells8. To specifically test whether this effect involved the expression of IL-7Rα in endothelial cells, we cre-
ated a mouse with an endothelial-specific deletion of the IL-7Rα (IL-7RαΔEC). To this end, we crossed mice that 
express the cre recombinase under the vascular endothelial (VE)-cadherin promotor (VE-cadherin-cre mice30) 
with IL-7Rαfl/fl mice31. qPCR analysis performed on DNA extracted from isolated LN LECs of IL-7RαΔEC mice 
(VE-cadherincre/cre x IL-7Rαfl/fl) and control mice (VE-cadherinwt/wt x IL-7Rαfl/fl, derived from the same line) sug-
gested deletion rates of approx. 97% (Suppl. Fig. 2) Similarly, fluorescence-activated cell sorting (FACS) analysis 
performed on LN single-cell suspensions indicated the absence of IL-7Rα (CD127) protein from LECs and blood 
endothelial cells (BECs) while it remained expressed in e.g. T cells (Suppl. Fig. 3). This analysis also confirmed 
our previous findings8 that, in comparison to IL-7Rα levels on T cells, expression in LECs and BECs is very low 
(Suppl. Fig. 3). No significant differences were observed in steady-state leukocyte populations analyzed by FACS 
performed on singe-cell suspensions in the ear skin or LNs of IL-7RαΔEC mice (Suppl. Figs 4 and 5). Analysis of 
lymphatic drainage did not reveal any differences in drainage under steady-state conditions (Fig. 1a), but drainage 
was significantly decreased in IL-7RαΔEC mice as compared to controls during acute inflammation induced by 
topical application of 12-O-tetradecanoyl phorbol-13-acetate (TPA) (Fig. 1b,c, Suppl. Fig. 6a). Notably, while a 
minute FACS signal for expression was observed in dermal LECs and BECs of TPA-inflamed control mice, this 
was consistently reduced in IL-7RαΔEC mice (Suppl. Fig. 6b–e). In line with reduced drainage, we also observed 
that TPA-induced inflammation led to a more profound ear swelling response in IL-7RαΔEC as compared to con-
trol mice (Fig. 1d). However, in spite of the edematous and seemingly more inflamed appearance, FACS analysis 
performed on singe-cell suspensions did not reveal any increase in leukocyte numbers in ear skin of IL-7RαΔEC 
compared to control mice (Fig. 1e–h). A trend towards decreased overall cellularity, T cell and DC numbers was 
seen in ear-draining auricular LNs of IL-7RαΔEC mice (Fig. 1i–l). Overall, these findings showed that during acute 
skin inflammation, loss of endothelial-cell expressed IL-7Rα reduced lymphatic drainage and exacerbated edema 
formation, i.e. one of the cardinal signs of inflammation.
mIL-7-Fc treatment exacerbates oxazolone-induced skin inflammation in K14-VEGF-A mice 
in spite of increased lymphatic drainage. We next set out to investigate the systemic impact of IL-7Rα 
signaling on chronic, psoriasis-like skin inflammation. In our previous study we had pharmacologically treated 
wild-type (WT) mice with IL-7/anti-IL-7 complexes to enhance drainage of dermal lymphatics in steady-state8. As 
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an alternative, more convenient tool for activating IL-7Rα signaling, we now generated a murine IL-7 Fc fusion pro-
tein (mIL-7-Fc) by fusing the sequence encoding mIL-7 with the hinge and Fc regions of murine immunoglobulin 1 
(IgG1) (Suppl. Fig. 7a–c). The biological activity of mIL-7-Fc was confirmed in vitro and in vivo by testing its ability 
to induce T cell proliferation and survival (Suppl. Fig. 7d–g). In comparison to IL-7/anti-IL-7 complexes, approx-
imately ten times (10x) higher molar equivalents of mIL-7-Fc were required to achieve the same degree of CD45+ 
leukocyte expansion in LNs and spleen, in line with previous reports of a similar IL-7-Fc fusion protein32. Therefore, 
this dose (mIL-7-Fc (10x)) was chosen for our in vivo inflammation studies (Suppl. Fig. 7e–g). Next, we investigated 
the effect of mIL-7-Fc treatment on the course of skin inflammation in K14-VEGF-A mice. The latter represent a 
well-recognized mouse model of psoriasis4,6,33–36. Homozygous K14-VEGF-A mice spontaneously develop inflam-
matory skin lesions at few weeks of age35. By contrast, in hemizygous mice, psoriasis-like chronic skin inflammation 
that persists over several weeks can be initiated by the induction of a contact hypersensitivity (CHS) response to 
oxazolone. At the site of challenge, i.e. the mouse ear, the inflamed skin is characterized by inflammatory cell infil-
tration, epidermal hyperproliferation, vascular expansion, and edema formation (Suppl. Fig. 8a)4,34,35. Accordingly, 
hemizyguous K14-VEGF-A mice were sensitized and challenged with oxazolone. Treatment with mIL-7-Fc was 
started seven days after challenge and continued for eight days (Fig. 2a, Suppl. Fig. 8b–e). Control groups were either 
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Figure 1. Endothelial-specific deletion of IL-7Rα decreases lymphatic drainage and increases edema formation 
in TPA-induced inflammation. (a) IL-7RαΔEC and control (CTR) mice were injected with a P20D800 conjugate 
i.d. in the uninflamed ear skin. Clearance of the tracer was monitored over 24 hours using an IVIS imaging 
system. Average clearance plots of P20D800 (left) and calculated half-lives (right) in CTR and IL-7Rα−/− mice 
(data from 1 experiment with 6 mice per group). (b) TPA (black arrow) was applied to the ears of IL-7RαΔEC 
and CTR mice on day 1. (c) Average clearance plots of P20D800 (left) and calculated half-lives (right) on day 
2 after TPA, assessed as in (A). (d) Ear thickness measurements between days 1–3. *** p < 0.001. FACS-based 
quantification of the number of (e,i) CD45+ cells, (f) CD3+ T cells, (g–l) DCs, (h) neutrophils, (j) CD4+ T cells, 
(k) CD8+ T cells in the ear skin (e–h) and dLNs (i–l) on day 3. Per animal, both ears and both ear-dLNs were 
pooled for the FACS analysis. Pooled data (mean ± SEM) from 2 similar experiments with a total of 11–12 mice 
per group are shown for (b–l).
4Scientific RepoRtS |         (2019) 9:11714  | https://doi.org/10.1038/s41598-019-48046-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
treated with KSF-Fc, i.e. an Fc-fusion of a single-chain variable fragment (scFv) directed against hen egg lysozyme37, 
or dexamethasone (i.e. a corticosteroid). While dexamethasone effectively reduced the inflammation-induced ear 
swelling response, treatment with mIL-7-Fc increased ear thickness with respect to the KSF-Fc control group, indic-
ative of an exacerbation of the inflammatory response (Fig. 2b). However, at the same time, lymphatic drainage 
improved significantly in mIL-7-Fc-treated mice compared to the KSF-Fc- and dexamethasone-treated groups 
(Fig. 2c,d). The increased ear thickness in the mIL-7-Fc treated mice compared to the KSF-Fc treated group was 
accompanied by an increase in the infiltration of CD45+ cells, such as CD4+ and CD8+ T cells (Fig. 2e–g), DCs and 
neutrophils (Fig. 2h,i) (for the FACS gating scheme see Suppl. Fig. 4). In addition, the exacerbated inflammation 
in the ear skin seen upon IL-7-Fc treatment led to a further expansion of the lymphatic and blood vessel area com-
pared to the control groups (Suppl. Fig. 9a–c). By contrast, analysis of keratin 6 and keratin 10 expression revealed 
no further exacerbation of epidermal thickening in the IL-7-Fc-treated group compared to the KSF-Fc-treated 
group (Suppl. Fig. 9d–f). Overall, these data indicated that mIL-7-Fc increased lymphatic drainage, but that the 
global stimulation of the immune response overrode this anti-inflammatory effect and resulted in exacerbated 
inflammation with a higher level of edema and immune cell infiltration.
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Figure 2. mIL-7-Fc treatment exacerbates oxazolone-induced inflammation in K14-VEGF-A mice in spite 
of increasing lymphatic drainage. (a) Hemizygous K14-VEGF-A mice were sensitized with oxazolone on the 
belly and paws. Five days later the ears were challenged with oxazolone. Mice were randomized into treatment 
groups of comparable ear thickness on day 7 and treated i.p. with mIL-7-Fc, KSF-Fc every second day, or 
with dexamethasone (Dexa) every day for one week. The ear thickness was measured on each treatment day. 
Lymphatic drainage was measured on day 14 after challenge, and the mice were sacrificed on day 15. Immune 
cell infiltration in the ear skin was analyzed by FACS. (b) Ear thickness measurements over the course of the 
treatment. P values indicated by an asterisk show comparisons between mIL7-Fc and KSF-Fc, and p values 
indicated by a pound sign show comparisons between Dexa and KSF-Fc. ###/***p < 0.001; ####/****p < 0.0001. 
(c,d) Lymphatic drainage analysis: (c) Average clearance plots of P20D800 measured by IVIS and (d) the 
calculated half-lives. FACS-based quantification of the number of (e) CD45+ cells, (f) CD4+ T cells, (g) CD8+ 
T cells, (h) DCs, (i) neutrophils in the ear skin on day 15. One ear per mouse was used for the FACS analysis. 
Pooled data (mean ± SEM) from 2 similar experiments with a total of 11–12 mice per group are shown.
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Anti-IL-7Rα treatment ameliorates oxazolone-induced skin inflammation in K14-VEGF-A 
mice. Since mIL-7-Fc exacerbated edema and immune cell infiltration, we hypothesized that treatment with 
an anti-IL-7Rα blocking antibody might ameliorate the inflammatory symptoms in the K14-VEGF-A model. To 
address this, we first measured the levels of known ligands of the IL-7Rα signaling pathway in the inflamed skin 
(Fig. 3a–c). Besides IL-7, thymic stromal lymphopoietin (TSLP), which is produced by dermal keratinocytes, is 
a second cytokine that signals through the IL-7Rα (when combined with the specific TSLPR chain)38,39. TSLP 
contributes to Th2 immunity and plays an important role in human allergic diseases38,39, but was also found to be 
upregulated in psoriatic skin lesions40. Interestingly, we found that also the TSLPR is expressed by murine LECs in 
vivo, and that TSLP induced lymphangiogenic processes in cultured human LECs in vitro (Suppl. Fig. 10). While 
there was no significant change in IL-7 levels (Fig. 3b), TSLP protein levels were profoundly increased in day 
8-inflamed skin (Fig. 3c). CD4+ effector/memory T cells in the inflamed ear skin expressed high levels of IL-7Rα, 
whereas its expression in the vasculature was very low (Suppl. Fig. 8b–e). Next, we investigated how IL-7Rα 
blockade would affect the progression of inflammation. Treatment with anti-IL-7Rα blocking antibody amelio-
rated edema in comparison to the IgG-treated group (Fig. 3d), while lymphatic drainage remained unchanged 
(Fig. 3e,f). In comparison to the IgG-treated group, infiltration of leukocytes (Fig. 3g–k) was similarly reduced in 
both the dexamethasone and the anti-IL-7Rα-treated groups. As a further indication of the down-modulation of 
the inflammatory response, the cellularity of the dLNs was reduced in the anti-IL-7Rα-treated compared to the 
IgG-treated group (Fig. 3l–o, FACS gating see Suppl. Fig. 4). In addition, treatment with either anti-IL-7Rα or 
dexamethasone induced a normalization of the vasculature in the inflamed ear skin (Suppl. Fig. 11). In combina-
tion with our findings showing that mIL-7Fc exacerbates inflammatory symptoms in spite of increased drainage, 
these data suggest that the effects of IL-7Rα signaling on the immune compartment are dominant over the effects 
on lymphatic drainage.
Anti-IL-7Rαtreatment ameliorates imiquimod-induced inflammation. Next, we tested whether 
the anti-IL-7Rα treatment would also ameliorate inflammation in another mouse model of psoriasis. Topical 
application of the toll-like receptor (TLR) 7/8 agonist imiquimod induces a psoriasis-like inflammation in the 
skin41. To establish inflammation, we applied imiquimod-containing cream to the ears of C57BL/6 mice every day 
for five days and every second day thereafter (Fig. 4a, Suppl. Fig. 12a). Also, in imiquimod-induced inflammation, 
CD4+ effector/memory T cells in the inflamed skin expressed considerable levels of IL-7Rα (Suppl. Fig. 12b–c). 
Conversely, the FACS signal for IL-7Rα expression detected in LECs and BECs was extremely low, yet consistently 
higher in control mice as compared to IL-7RαΔEC mice (Suppl. Fig. 12d,e). IL-7 expression was undetectable 
in the ear skin by ELISA, but TSLP levels were increased at the peak of imiquimod-induced inflammation on 
day 8 (Fig. 4b,c). Also in this model treatment with anti-IL-7Rα ameliorated edema (Fig. 4d) without detecta-
ble changes in lymphatic drainage (Fig. 4e,f). By contrast, anti-IL-7Rα treatment led to decreased immune cell 
infiltration in the ear (Fig. 4g–j) and a slight albeit not significant reduction in cellularity of the dLN (Fig. 4k–n). 
These data confirm the involvement of the IL-7Rα pathway in the pathogenesis of psoriasis in another mouse 
model and highlight the therapeutic potential of blocking IL-7Rα signaling.
Endothelial-specific deletion of IL-7Rα decreases lymphatic drainage and increases edema 
formation in imiquimod-induced inflammation. We showed that IL-7Rα stimulation exacerbated 
edema and immune cell infiltration, while IL-7Rα blockade resolved inflammatory symptoms. The effects of 
IL-7Rα stimulation or blockade therefore seemed to primarily be dictated by its effect on the immune response. 
To investigate whether loss of IL-7Rα signaling in endothelial cells would have any impact on the progres-
sion of inflammation and on lymphatic function in chronic, psoriasis-like skin inflammation, we established 
imiquimod-induced skin inflammation in IL-7RαΔEC mice (Fig. 5a). IL-7RαΔEC mice developed more severe 
edema in the ear compared to control mice (Fig. 5b). In line with these findings, a near-significant decrease in 
lymphatic drainage was observed in the ear skin of IL-7RαΔEC mice (Fig. 5c,d). No difference in overall CD45+ 
leukocytes (Fig. 5e) or neutrophils (Fig. 5f) were seen, but CD3+ T cell (Fig. 5g) and DC (Fig. 5h) numbers were 
significantly reduced in ear skin of IL-7RαΔEC as compared to control mice. At the same time, no significant dif-
ferences in leukocyte populations in the dLNs were observed (Fig. 5i–l). This indicates that the increased edema 
and near-significant reduction in lymphatic drainage seen in imiquimod-induced inflammation in IL-7RαΔEC 
mice was due to the effects of IL-7Rα signaling on lymphatic function.
Discussion
In this study, we dissected the role of IL-7Rα signaling in mouse models of acute or psoriasis-like, chronic skin 
inflammation. We found that IL-7Rα signaling had opposing effects on endothelial cells and on leukocytes in the 
regulation of skin inflammation: endothelial-specific genetic deletion of the IL-7Rα resulted in increased edema 
formation as a consequence of impaired lymphatic drainage, while the effects on the inflammatory cell infiltrate 
were largely unchanged. These data illustrate the importance of lymphatic drainage for the resolution of inflam-
matory edema in the skin, in accordance with previous studies4–6,42. By contrast, when systemically enhancing 
or blocking IL-7Rα signaling in mice with normal IL-7Rα expression, we found that the effects on the immune 
compartment dominated the inflammatory response, and IL-7Rα signaling contributed to the exacerbation of 
psoriasis-like symptoms.
In line with our previous findings8, we observed that under steady-state conditions lymphatic drainage was 
reduced in IL-7Rα−/− mice, while it was increased in mice treated with mIL-7-Fc. In the context of psoriasis-like 
skin inflammation, treatment with mIL-7-Fc resulted in a profound exacerbation of the inflammatory symptoms. 
Nevertheless, we observed an increase in lymphatic drainage upon mIL-7-Fc treatment compared to KSF-Fc and 
dexamethasone treatment in this model. Given that there was no correlation between lymphatic drainage and 
the increase in ear thickness in KSF-Fc- and dexamethasone-treated mice (which do have a significant difference 
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Figure 3. Anti-IL-7Rα treatment ameliorates oxazolone-induced inflammation in K14-VEGF-A mice. (a) 
Hemizygous K14-VEGF-A mice were sensitized with oxazolone on the belly and paws. Five days later their ears were 
challenged with oxazolone. Mice were randomized into treatment groups on day 7 and treated i.p. with anti-IL-7Rα 
antibody, corresponding IgG control, or with dexamethasone (Dexa) on days 7, 9, 11, and 13. The ear thickness was 
measured on each treatment day. Lymphatic drainage was measured on day 14 after challenge, and the mice were 
sacrificed on day 15. Immune cell infiltration in the ear skin and dLNs was analyzed by FACS. (b) IL-7 and (c) TSLP 
protein levels were measured from ear skin lysates on day 8 (n = 4 per group). (d) Ear thickness measurements over 
the course of the treatment. P values indicated by an asterisk show comparisons between anti-IL-7Rα and IgG. P 
values indicated by a pound sign show comparisons between Dexa and IgG. #/*p < 0.05; **p < 0.01 ###p < 0.001; 
####p < 0.0001. (e,f) Lymphatic drainage analysis: (e) Average clearance plots of P20D800 from the ear measured by 
IVIS and (f) the calculated half-lives. FACS-based quantification of the number of (g,l) CD45+ cells, (h,m) CD4+ 
T cells, (i,n) CD8+ T cells, (j,o) DCs, (k) neutrophils measured in the ear skin (g–k) and in dLNs (l–o) on day 15. 
One ear per mouse and both dLNs were used for the FACS analysis. Data (mean ± SEM) from 1 out of 3 similar 
experiments (d,g–k) and data from 1 out of 2 experiments with each 5–7 mice per group (e,f,l–q) are shown.
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Figure 4. Anti-IL-7Rα treatment ameliorates imiquimod-induced inflammation in WT mice. (a) Imiquimod-
containing cream was applied to the ears on day 1, 2, 3, 4, 5, 7, 9, 11, and 13. Mice were randomized into 
treatment groups on day 7 and treated i.p. with anti-IL-7Rα antibody, corresponding IgG control, or with 
dexamethasone (Dexa) on days 7, 9, 11, and 13. The ear thickness was measured on each treatment day. 
Lymphatic drainage was measured on day 14 and the mice were sacrificed on day 15. Immune cell infiltration 
in the ear skin and dLNs was analyzed by FACS. (b) IL-7 and (c) TSLP protein levels were measured from ear 
skin lysates on day 8. (d) Ear thickness measurements over the course of the treatment. P values indicated by an 
asterisk show comparisons between anti-IL-7Rα and IgG. P values indicated by a pound sign show comparisons 
between Dexa and IgG. #/*p < 0.05; ##/**p < 0.01; ***p < 0.001. (e,f) Lymphatic drainage analysis: (e) Average 
clearance plots of P20D800 from the ear measured by IVIS and (f) the calculated half-lives. FACS-based 
quantification of the number of (g,k) CD45+ cells, (h) CD3+ T cells, (i,n) DCs, (j) neutrophils, (l) CD4+ T cells, 
(m) CD8+ T cells measured in the ear skin (g–j) and dLNs (k–n) on day 15. Both ears and dLNs were pooled for 
the FACS analysis. Data (mean ± SEM) from 1 experiment with 4–6 mice per group are shown.
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ear thickness) the enhanced drainage rates observed in the mIL-7-Fc treated group cannot simply be explained 
by the exacerbated edema. In fact, in comparison to steady-state conditions, lymphatic drainage was reportedly 
decreased in oxazolone-induced inflammation in K14-VEGF-A mice4,43. This strongly suggests that the increase 
in drainage seen upon treatment with mIL-7-Fc was caused by IL-7’s drainage promoting activity. Interestingly, 
treatment with anti-IL-7Rα did not result in a decrease in lymphatic drainage in the two inflammation models 
tested (K14-VEGF-A and imiquimod model). This might be explained by the much higher IL-7Rα expression 
on leukocytes compared to endothelial cells, which favors antibody binding and blocking activity on leukocytes. 
Blocking the low IL-7Rα levels on endothelial cells and particular on LECs, which constitutively produce the 
IL-7Rα ligand IL-78, is likely much more challenging. This failure to inhibit autocrine IL-7/IL-7Rα signaling in 
LECs might therefore explain why drainage was not reduced in anti-IL-7Rα-treated mice. Of interest, autocrine 
VEGF-A signaling in endothelial cells is known to be indispensable for endothelial survival, but to occur mainly 
through intracellular autocrine receptor binding and signaling44. Similar to our findings with anti-IL-7Rα treat-
ment, this survival promoting function of VEGF-A was apparent in endothelial cell-specific VEGF-A knockouts 
but could not be observed upon treatment with anti-VEGF-A antibody44.
In our previous study we had observed that the drainage-promoting activity of IL-7Rα signaling depended 
on IL-7Rα expression in stromal cells8. Here, we show that genetic deletion of IL-7Rα in endothelial cells suffices 
to modulate lymphatic drainage. Even though no drainage defect was observed in IL-7RαΔEC mice under steady 
state, drainage was decreased upon TPA and imiquimod-induced inflammation. In both TPA-induced acute 
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Figure 5. Endothelial-specific deletion of IL-7Rα decreases lymphatic drainage and increases edema 
formation in imiquimod-induced inflammation. (a) Imiquimod-containing cream was applied to the ears of 
IL-7RαΔEC and control (CTR) mice on days 1–5, and 7. The ear thickness was measured on each treatment day. 
Lymphatic drainage was measured on day 7 after challenge and the mice were sacrificed on day 8. The immune 
cell infiltration in the ear skin was analyzed by FACS. (b) Ear thickness measurements over the course of the 
treatment. *p < 0.05; **p < 0.01. (c,d) Lymphatic drainage analysis: (c) Average clearance plots of P20D800 
from the ear measured by IVIS and (d) the calculated half-lives. FACS-based quantification of the number of 
(e,i) CD45+ cells, (f) neutrophils, (g) CD3+ T cells, (h,l) DCs, (j) CD4+ T cells, (k) CD8+ T cells in (e–h) the ear 
skin and (i–l) dLNs on day 8. The average number of immune cells per ear is shown. Pooled data (mean ± SEM) 
from 3 experiments with a total of 17–18 mice per group (b,e–l) and pooled data from 2 experiments with 8–12 
mice per group (c,d) are shown.
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and imiquimod-induced chronic inflammation, reduced drainage was accompanied by a significant increase 
in ear thickness (i.e. tissue edema) in IL-7RαΔEC mice. By contrast, upon systemic treatment with anti-IL-7Rα, 
the ear swelling response was profoundly reduced whereas drainage was not altered. The differential effects of 
anti-IL-7Rα and endothelial IL-7Rα deletion on the ear swelling response can likely be explained as follows: upon 
systemic blockade of IL-7Rα, levels of infiltrating leukocytes were strikingly reduced both in the K14-VEGF-A 
and in the imiquimod-induced skin inflammation model. It is fair to assume, that in presence of fewer cellu-
lar infiltrates also less inflammatory mediators were produced, resulting in less blood vascular leakage and 
inflammation-induced edema. Considering that lymphatic drainage was not reduced under these conditions 
(likely because antibody treatment failed to block autocrine IL-7/IL-7Rα signaling in LECs), the decrease in 
ear thickness can mainly be attributed to treatment-induced reduction in leukocyte infiltration and activation. 
Conversely, in the genetic model, in which IL-7Rα was lacking in endothelial cells but leukocyte infiltration was 
in large parts unaffected, the reduced lymphatic drainage accounted for the increased ear thickness measured in 
the IL-7RαΔEC mice.
While mIL-7-Fc exacerbated psoriasis-like inflammation, anti-IL-7Rα treatment improved edema, reduced 
immune cell infiltration, and decreased the cellularity of the dLN. The anti-inflammatory effects of the anti-IL-
7Rα treatment are likely mediated by the blockade of IL-7Rα signaling in immune cells. It is well known that IL-7 
expands the naive and memory T cell pool9, but in accordance with our own findings, recent studies have also 
shown IL-7Rα expression in effector T cells45,46. Moreover, there are several studies showing that IL-7 supports 
the expansion and function of Th1 and Th17 responses11–14, which are considered the main drivers of human 
psoriasis24, and also relevant in the K14-VEGF-A33,47 and imiquimod-induced41 skin inflammation models used 
in this study. In addition to impacting homeostasis and function of conventional αβ T cells, IL-7 is also necessary 
for the survival of γδ T cells48, which were shown to be important IL-17 producers and drivers of inflammation in 
the K14-VEGF-A and imiquimod-induced inflammation models47,49. Thus, similarly to its suggested activity in 
other mouse models of autoimmunity13,19–22, anti-IL-7Rα treatment likely reduced the Th1 and Th17 response in 
the psoriasis-like skin inflammation investigated here.
At present, we do not know whether the observed anti-inflammatory effects of anti-IL-7Rα treatment were 
entirely due to blocking IL-7 or also due to blocking TSLP. In contrast to the reported upregulation of IL-7 in 
human psoriasis26,28, we did not observe an upregulation of IL-7 in the inflamed murine ear skin. However, this 
does not exclude that local levels of IL-7 produced by LECs or keratinocytes in the skin were sufficient to support 
IL-7-mediated responses of effector T cells in the inflamed tissue. Furthermore, anti-IL-7Rα treatment likely does 
not only act locally, at the site of inflammation, but rather also reduces IL-7Rα signalling in secondary lymphoid 
organs, where high amounts of IL-7 are constantly produced by stromal cells9.
In agreement with a study reporting its expression in human psoriatic skin lesions40, TSLP was markedly 
upregulated in inflamed murine skin, suggesting that inflammation-induced TSLP could also modulate lym-
phatic drainage and the immune response. In further support of this notion, our data showed that TSLP induced 
lymphangiogenic processes in LECs in vitro. However, in contrast to IL-7, TSLP does not appear to be expressed 
in LECs in vivo50. Given that local concentrations of IL-7 in the vicinity of/within LECs are expected to be very 
high and that at the same time IL-7Rα expression on LECs is very low, it is unlikely that inflammation-induced 
TSLP can effectively compete with the autocrine IL-7/IL-7Rα signalling in LECs. On the other hand, TSLP could 
also modulate the inflammatory response, by affecting T cell polarization and effector function. TSLP is strongly 
linked with the induction and maintenance of Th2 responses38,39. However, considering that skin inflammation 
induced by imiquimod41 and in K14-VEGF-A mice33,47 carries a Th17 signature, it seems rather unlikely that 
TSLP is the main driver of the IL-7Rα-mediated inflammatory responses in our models. Furthermore, Th17 cells 
reportedly express much lower levels of TSLPR than Th2 cells, which are considered the primary TSLP target 
cells51. Besides its expression on T cells, also dendritic cells (DCs) express the TSLPR, and TSLP is well known for 
its ability to polarize DCs to induce T cell activation and differentiation into Th2 cells38,39. Interestingly, a recent 
study also reported a role for TSLP in inducing the production of the Th17-promoting cytokine IL-23 in human 
DCs40. Thus, although the current literature would suggest a more prevalent role for IL-7 thanks to its Th1- and 
Th17- promoting activity, a potential contribution of TSLP to psoriasis-like skin cannot be ruled out at present.
Overall, our data describe a new role for IL-7Rα signaling in the progression of psoriasis-like skin inflamma-
tion. We show for the first time that blocking IL-7Rα signaling improves psoriasis-like inflammation and might 
be a valuable therapeutic target. This is of particular relevance, considering that a first antibody targeting IL-7Rα 
is currently in clinical development23.
Methods
Mice. WT C57BL/6 mice were purchased from Janvier (Janvier, Saint-Isle, France). IL-7Rα−/−8,52 and hem-
izygous K14-VEGF-A transgenic mice (referred to as K14-VEGF-A)34,35 have been previously described. Mice 
with an endothelial-specific knockout of the IL-7Rα, driven by the VE-cadherin promotor (referred to as 
IL-7RαΔEC mice), were created by crossing VE-cadherin cre mice30 with IL-7Rαfl/fl mice (Jackson31 Laboratory, 
Bar Harbor, USA). A control mouse line was established from the same genetic background as IL-7RαΔEC mice 
(i.e. VE-cadherinwt/wt x IL-7Rαfl/fl mice). The deletion efficiency in IL-7RαΔEC mice was determined by quanti-
tative PCR on LECs isolated from LNs, as described in the online Supplementary Methods. All mice were bread 
under specific pathogen free (SPF) conditions in the ETH Rodent Center HCI facility. Experiments were per-
formed using groups of 8–13 weeks old, age- and sex-matched animals.
Approval. All in vivo experiments in mice were approved by the Cantonal Veterinary Office Zurich (protocol 
numbers 268/2014 & 238/2017), and all methods were performed in accordance with the relevant guidelines and 
regulations.
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Cloning, expression, purification and activity of mIL-7-Fc. See Supplemental Methods.
Oxazolone-induced inflammation in K14-VEGF-A mice. A CHS response was induced in 
K14-VEGF-A mice as described previously4. In brief, mice were anesthetized by inhalation of anesthe-
sia (isoflurane, 2.5%, Piramal Enterprises, Mumbai, India). The belly was shaved with a razor. 2% oxazolone 
(4-ethoxymethylene-2-phenyl-2-oxazoline-5-1, Sigma-Aldrich) in acetone/olive oil (4/1 v:v) were applied to the 
belly (50 μl) and to each paw (5 μl). Mice were kept under anesthesia for approximately 20 minutes to ensure 
absorption of oxazolone by the skin. After 5 days mice were challenged with 10 μl 1% oxazolone in acetone/
olive oil (4/1 vol:vol) on each side of the ear and the baseline ear thickness was determined using an ear cali-
per (Brütsch Rüegger, Urdorf, Switzerland). After 7 days mice were anesthetized with inhalation of anesthesia 
(isoflurane, 2.5%) and the ear thickness was measured. Mice were randomized into 3 treatment groups with 
equal average increase in ear thickness and similar standard deviation in each group. Mice were treated i.p. with 
37 μg mIL-7-Fc or corresponding control fusion protein (KSF-Fc; non-specific single chain Fv antibody fragment 
against hen egg lysozyme53, fused to an IgG1 Fc fragment, and produced in our lab37, or 400 μg anti-IL-7α block-
ing antibody (clone A7R34, Bioexcell, West Lebanon, USA) or corresponding IgG control (clone 2A3, Bioexcell) 
every other day. I.p. treatment (100 μg) with dexamethasone (Mepha, Switzerland) was either given every day or 
every other day54, as indicated in the experimental layout in Figs 2a, 3a or 4a. Ear thickness was measured on all 
treatment days. Lymphatic drainage was assessed on day 14. Mice were sacrificed on day 15. Ears and dLN were 
harvested for further analysis by FACS or immunofluorescence.
Imiquimod-induced inflammation. C57BL/6 mice were anesthetized by inhalation of anesthesia (isoflu-
rane, 2.5%). The baseline ear thickness was measured using an ear caliper (Brütsch Rüegger, Urdorf, Switzerland). 
Imiquimod-containing cream (Aldara 5% (50 mg/g), Mepha, Switzerland) was applied with a spatula to the two sides 
of each ear (approximately 30 mg of cream per mouse). Cream was applied on day 1–5, 7, 9, 11, and 13 and the ear 
thickness was determined. In some cases, an additional dose of imiquimod was given on day 6. On day 7, when the 
peak in ear thickness was reached (±200 μm increase from baseline), mice were randomized into 3 treatment groups 
with an equal average increase in ear thickness and similar standard deviation in each group. Mice were treated 
i.p. with 400 μg anti-IL-7Rα blocking antibody (clone A7R34, Bioexcell) or corresponding IgG control (clone 2A3, 
Bioxcell), or 100 μg dexamethasone (Mepha) on days 7, 9, 11, and 13 after oxazolone challenge. Lymphatic drainage 
was assessed on day 14. Mice were sacrificed on day 15. Ears and dLNs were harvested for further analysis by FACS.
In some experiments the establishment of imiquimod-induced inflammation was studied in IL-7RαΔEC mice 
and in the corresponding control mice (CTR: VE-cadherinwt/wt x IL-7Rαfl/fl mice). Lymphatic drainage was deter-
mined on day 7. Mice were sacrificed on day 8 and the ears and dLNs were harvested for analysis by FACS.
Acute TPA-induced inflammation. IL-7RαΔEC mice and the corresponding control mice were anes-
thetized by inhalation of anesthesia (isoflurane, 2.5%). The baseline ear thickness was measured using an ear 
caliper (Brütsch Rüegger, Urdorf, Switzerland) and 1 μg 12-O-tetradecanoylphorbol 13-acetate (TPA/PMA, 
Sigma-Aldrich) in acetone (Sigma-Aldrich) was applied to each side of the ear on day 1. Lymphatic drainage 
was measured on day 2 and mice were sacrificed on day 3. The ears and dLNs were harvested for analysis by 
FACS.
fAcS analysis of ear and Ln single-cell suspensions. Different immune cell populations in ears, LNs, 
and spleen were analyzed by FACS. To this end single cell suspensions were created as previously described55. 
In brief, mice were sacrificed and the ears and LNs were harvested. Ears were split along the cartilage and cut in 
small pieces. Ears and LNs were digested in PBS containing 4 mg/ml collagenase type IV (Thermo Fisher) for 
45 minutes at 37 °C. LNs and spleens that were used to determine leukocyte expansion after mIL-7-Fc treatment 
were not digested. Tissues were passed through a 40-μm cell strainer, centrifuged, resuspended in FACS buffer 
(PBS containing 2% FCS (Thermo Fisher) and 2 mM EDTA (Sigma-Aldrich)), and filtered through a 40-μm filter 
tube. Splenocytes were subjected to red blood cell lysis after straining by incubation with ACK buffer contain-
ing 150 mM ammonium chloride (Sigma-Aldrich), 10 mM potassium bicarbonate (Sigma-Aldrich), and 0.1 mM 
EDTA-Na2 (Sigma-Aldrich) for 5 minutes on ice. AccuCheck counting beads (Thermo Fisher) or Flow-Count 
Fluorospheres (Beckman Coulter, Brea, USA) were added to the samples after cell straining to enable absolute 
cell quantification. Samples were stained with antibodies in FACS buffer for 20 minutes on ice using the follow-
ing anti-mouse antibodies (all from Biolegend, unless noted): CD45-PerCP, CD45-APC/Cy7 or CD45-PE/Cy7 
(clone 30F-11), CD4-PE, CD4-FITC or CD4-APC (clone GK1.5), CD8a-FITC (clone 53-6.7), CD3-APC (clone 
145-2C11), TCRβ-PE/Cy7 or TCRβ-Brilliant Violet 421 (clone H57-597), CD44-FITC or CD44-APC (clone 
IM7), Ly6G-PerCP/Cy5.5 or Ly6G-PE (clone 1A8), CD11c-APC or CD11c-PE/Cy7 (clone N418), CD11b-FITC 
(clone M1/70), MHCII-PE or MHCII-BV421 (clone M5/114.15.2), podoplanin-APC (clone 8.1.1), CD31-FITC 
(clone MEC 13.3, from BD Biosciences), CD127-PE (clone SB/199) and the corresponding isotype control (rat 
IgG2b-PE, clone RTK4530). In all experiments an Fc receptor blocking step with anti-mouse CD16/32 (clone 
93) was performed prior to FACS staining, and a live/dead cell staining with zombie-NIR or zombie-Aqua (both 
from Biolegend) was performed prior to recording. All FACS samples were acquired on a FACS Canto (BD 
Bioscience) using FACSDiva software (BD Bioscience) or on a Cytoflex (Beckman Coulter) using CytExpert 
Software (Beckman Coulter). Data were analyzed using FlowJo software (Treestar). All other FACS analyses are 
described in the online Supplemental Methods.
Protein extraction from ear lysates. Harvested ears were split along the cartilage and cut into small 
pieces. 500 μl lysis buffer (10 ml, containing 50 mM Tris, 150 mM NaCl (Sigma-Aldrich), and a cOmplete 
Mini EDTA-free Protease Inhibitor Cocktail tablet (Sigma-Aldrich)) and a stainless steel metal bead (Qiagen, 
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Hombrechtikon, Switzerland) were added to the ear pieces. Tissues were homogenized 4 times for 60 seconds 
at maximum speed using a Tissue Lyser (Qiagen). Subsequently, tissues were centrifuged, the supernatant was 
collected, and sent for IL-7 and TSLP determination to Cytolab for analysis with a multiplexed particle-based 
cytometric cytokine assay (Regensdorf, Switzerland).
Lymphatic drainage assay. The lymphatic drainage assay was performed as previously described29,56. In 
brief, mice were anesthetized by inhalation of anesthesia (isoflurane, 2.5%) and the base of the ears were shaved 
with a razor. Three μl P20D800 (3 μM- synthesized as described in the online Supplemental Methods) were 
injected i.d. into the ear skin using a 29G insulin syringe (Terumo,Tokyo, Japan). Subsequently, the mouse was 
placed into an IVIS imaging system (Perkin Elmer, Waltham, MA) with the ears taped down flat and a fluorescence 
image (λex = 745 nm, λem = 800 nm, exposure time 4 seconds, binning 2) was acquired. Imaging was repeated 1, 
2, 4, 6, and 24 hours after injection. Mice were housed in their cages in between imaging time points and anesthe-
tized by inhalation of isoflurane for approximately 5 minutes for each imaging session. For the analysis, regions of 
interest (ROI) were drawn around the ears and the average fluorescence intensity was measured in each ROI using 
Living Image 4.0 software (Perkin Elmer). After subtracting the background fluorescence intensity of uninjected 
ears, the average fluorescence intensities in each ROI were normalized to the initial amount of dye injected (aver-
age fluorescence intensity at time 0). The normalized average fluorescence intensities were plotted against time and 
fitted to a one-phase exponential decay model from which the tracer clearance half-life was determined.
Immunofluorescence staining and analysis of ear sections. See Supplemental Methods.
Statistical analysis. Graphs were generated in GraphPad prism 7 (La Jolla, USA) and statistical analysis 
was performed using the same software. The student t-test (unpaired, two-tailed) was used when comparing two 
groups. One-way ANOVA with a Tukey-post hoc test was used to compare three or more groups. For comparison 
of more than two groups in repeated measurements (i.e. ear thickness measurements) a 2-way ANOVA with 
Bonferroni correction was used. Differences were considered statistically significant when p < 0.05. Mean and 
standard error of the mean (SEM) are shown.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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